Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCorp RxTSXV:PCRX 35 Receivables Turnover is 5.98 as of Mar. 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 658 Healthcare Providers & Services companies, PharmaCorp Rx ranks better than 89.21% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PharmaCorp Rx's Revenue for the
three
months ended in Mar. 2026 was C$7.19 Mil. PharmaCorp Rx's average Accounts Receivable for the
three
months ended in Mar. 2026 was C$1.20 Mil.
Hence, PharmaCorp Rx's Receivables Turnover for the
three
months ended in Mar. 2026 was 5.98.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PharmaCorp Rx Receivables Turnover Related Terms
PharmaCorp Rx Receivables Turnover Historical Data
* Premium members only.
The historical data trend for PharmaCorp Rx's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a Receivables Turnover of 5.98 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #71 out of 658 companies in the Healthcare Providers & Services industry, placing it in the top 10.8%.
Is PharmaCorp Rx's Receivables Turnover too high?
PharmaCorp Rx's current Receivables Turnover is 5.98. The Healthcare Providers & Services industry median Receivables Turnover is 7.78. PharmaCorp Rx's value of 5.98 is 23.1% below this industry median. Based on the distribution chart, PharmaCorp Rx ranks #71 out of 658 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaCorp Rx has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's Receivables Turnover compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #71 out of 658 companies for Receivables Turnover. This places PharmaCorp Rx in the top 11% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 7.78. PharmaCorp Rx's value of 5.98 is 23.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.78, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCorp Rx's current Receivables Turnover of 5.98 is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PharmaCorp Rx and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current Receivables Turnover is 5.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current Receivables Turnover of 5.98. The current Receivables Turnover is 5.98 and 23.1% below the Healthcare Providers & Services industry median of 7.78. PharmaCorp Rx's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current Receivables Turnover is 5.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
35GF Score
Get the complete analysis for TSXV:PCRX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
